Trial Review

Please note the ANZCTR will be unattended from Friday 20 December 2024 for the holidays. The Registry will re-open on Tuesday 7 January 2025. Submissions and updates will not be processed during that time.

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12623000302651
Ethics application status
Approved
Date submitted
23/02/2023
Date registered
17/03/2023
Date last updated
16/11/2023
Date data sharing statement initially provided
17/03/2023
Type of registration
Prospectively registered

Titles & IDs
Public title
Feasibility of a group cognitive behavioural therapy (CBT) program for trans young people experiencing minority stress
Scientific title
Evaluation of a group cognitive behavioural therapy (CBT) program for trans young people experiencing minority stress: A feasibility trial of the Trans Adolescent Group ThErapy for Alleviating Minority stress (TAG TEAM) intervention
Secondary ID [1] 309068 0
None
Universal Trial Number (UTN)
U1111-1288-1842
Trial acronym
Linked study record
N/A

Health condition
Health condition(s) or problem(s) studied:
Depression 329126 0
Anxiety 329127 0
Minority Stress 329128 0
Condition category
Condition code
Mental Health 326101 326101 0 0
Depression
Mental Health 326102 326102 0 0
Anxiety
Mental Health 326297 326297 0 0
Other mental health disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
The intervention is the Trans Adolescent Group ThErapy for Alleviating Minority stress (TAG TEAM) program, which is a group cognitive behavioural therapy (CBT) program that focuses on experiences of minority stress.

The TAG TEAM program was developed with trans young people in a co-design process. Trans young people who had attended the Royal Children’s Hospital Gender Service (RCHGS) participated in one 2-hour workshop and two 1.5-hour workshops over 6 weeks, during which they shared their experiences of being on the waitlist for and attending RCHGS, experiences of being a transgender young person, preferences for the content and delivery of a mental health intervention, and their opinions on the proposed mental health intervention.

The TAG TEAM program sessions focus on themes related to minority stress and factors that protect against minority stress (e.g., community connectedness, discrimination and rejection, internalised stigma, pride), and CBT principles that will assist young people to manage their cognitive, emotional, and behavioural responses to minority stress (e.g., assigning and reviewing between-session activities, learning, and practicing techniques).

The TAG TEAM program sessions are designed to include group discussion of the session themes, psychoeducation on CBT principles, activities practicing CBT techniques and skills, videos of trans adults exploring the session themes, and the assigning of between-session activities. Between-session activities will take approximately 1-2 hours per week during the program.

The program consists of six two-hour sessions conducted weekly, either in-person at the Royal Children’s Hospital, Victoria or online via teleconferencing software. The program will be delivered and facilitated by a psychologist and trans peer worker with experience working with young people. 8 participants will be allocated to each group.

The TAG TEAM program is manualised, and the facilitators will be trained in the treatment protocol by a senior clinician in the research team. The fidelity to the treatment protocol will be assessed by facilitators using a checklist at the end of each session to indicate whether each activity in the protocol was (0) not completed, and if so, a reason for non-completion, (1) partially completed, and if so, a reason for partial completion, or (2) completed. The fidelity ratings will be collated by a member of the research team and the facilitators will review their adherence to the protocol in fortnightly supervision sessions with a senior clinician in the research team.
Intervention code [1] 325511 0
Treatment: Other
Intervention code [2] 325512 0
Behaviour
Comparator / control treatment
There is no control group.
Control group
Uncontrolled

Outcomes
Primary outcome [1] 333972 0
Intervention completion rate via participation logs. Assessed via audit of study logs.
Timepoint [1] 333972 0
Post-completion of treatment period
Primary outcome [2] 333973 0
Intervention safety via adverse events log. Assessed via audit of study logs.
Timepoint [2] 333973 0
Post-completion of treatment period
Primary outcome [3] 333974 0
Participant evaluation of intervention as feasible and acceptable via TAG TEAM participant evaluation survey
Timepoint [3] 333974 0
Post-completion of treatment period
Secondary outcome [1] 418894 0
Facilitator evaluation of intervention as feasible and acceptable via self-developed survey. This is an additional primary outcome.
Timepoint [1] 418894 0
Post-completion of treatment period
Secondary outcome [2] 418895 0
Comparison of in-person and online intervention recruitment and completion rate via participation logs. Assessed via audit of study logs.
This is an additional primary outcome.
Timepoint [2] 418895 0
Post-completion of treatment period
Secondary outcome [3] 418896 0
Trial eligibility rate via recruitment logs. Assessed via audit of study logs.
Timepoint [3] 418896 0
Post-completion of treatment period
Secondary outcome [4] 418897 0
Trial participation rate via recruitment logs. Assessed via audit of study logs.
Timepoint [4] 418897 0
Post-completion of treatment period
Secondary outcome [5] 418898 0
Trial lost to follow-up rate via participation logs. Assessed via audit of study logs.
Timepoint [5] 418898 0
Post-completion of treatment period
Secondary outcome [6] 419611 0
Trial outcome measure completion rate via outcome measure data. Assessed via audit of study logs.
Timepoint [6] 419611 0
Post-completion of treatment period
Secondary outcome [7] 419612 0
Treatment protocol adherence via facilitator logs. Assessed via audit of study logs.
Timepoint [7] 419612 0
Post-completion of treatment period

Eligibility
Key inclusion criteria
Inclusion criteria are:

(1) Is trans or gender diverse
(2) Has been referred to the RCHGS but has not attended a Multidisciplinary Assessment Clinic (MDAC) appointment
(3) Is between the ages of 14 and 16 years at the time of enrolment into the study
(4) Has current depressive or anxious symptomology as determined by a total score of 8 or above on the Short Mood and Feelings Questionnaire (indicating elevated depressive symptomatology) or a T score of 60 or above on the Spence Children’s Anxiety Scale (indicating elevated anxious symptomatology)
(5) Ability and willingness of participant and legally acceptable representative to give written informed consent
Minimum age
14 Years
Maximum age
16 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Exclusion criteria are:

(1) Has an Multidisciplinary Assessment Clinic (MDAC) appointment booked within 6 months
(2) Has current suicidal symptomology as determined by receiving a score of 3 or above on the Columbia-Suicide Severity Rating Scale
(3) Is actively having treatment with any other group psychological intervention at the time of enrolment into the study
(4) Is not proficient in English (as the group CBT program will be delivered in English and funds aren’t available for interpreters)

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Participants will complete the group program either in person (n = 16) or via teleconferencing software (n = 16).
Phase
Not Applicable
Type of endpoint/s
Safety
Statistical methods / analysis
As the objective of the feasibility trial is to evaluate the feasibility and acceptability of the intervention and study design rather than to assess the efficacy of the intervention, there is no statistical justification of sample size needed. We determined the sample size through a consideration of what is necessary to determine feasibility and acceptability while accounting for attrition.

A sample size of 32 participants will allow us to evaluate the feasibility and acceptability of the intervention and study design, with two groups being delivered in person and two groups being delivered via teleconferencing software enabling evaluation of acceptability of delivery method.

The analysis will use the intention-to-treat population. The analysis will use descriptive statistics including means, medians, counts and proportions to assess the recruitment, baseline and outcome data.

Recruitment
Recruitment status
Recruiting
Date of first participant enrolment
Anticipated
5/10/2023
Actual
20/10/2023
Date of last participant enrolment
Anticipated
10/11/2023
Actual
Date of last data collection
Anticipated
29/03/2024
Actual
Sample size
Target
32
Accrual to date
8
Final
Recruitment in Australia
Recruitment state(s)
VIC
Recruitment hospital [1] 24122 0
The Royal Childrens Hospital - Parkville
Recruitment postcode(s) [1] 39630 0
3052 - Parkville

Funding & Sponsors
Funding source category [1] 313272 0
Charities/Societies/Foundations
Name [1] 313272 0
Royal Children's Hospital Foundation
Country [1] 313272 0
Australia
Primary sponsor type
Other Collaborative groups
Name
Murdoch Children's Research Institute
Address
Royal Children's Hospital
50 Flemington Road
Parkville, VIC 3052
Country
Australia
Secondary sponsor category [1] 315010 0
None
Name [1] 315010 0
Address [1] 315010 0
Country [1] 315010 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 312503 0
Royal Children’s Hospital Human Research Ethics Committee
Ethics committee address [1] 312503 0
Ethics committee country [1] 312503 0
Australia
Date submitted for ethics approval [1] 312503 0
27/10/2022
Approval date [1] 312503 0
19/12/2022
Ethics approval number [1] 312503 0
91162

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 124894 0
A/Prof Ken Pang
Address 124894 0
Murdoch Children's Research Institute
Royal Children's Hospital
50 Flemington Road, Parkville VIC 3052
Country 124894 0
Australia
Phone 124894 0
+61 393456991
Fax 124894 0
Email 124894 0
ken.pang@mcri.edu.au
Contact person for public queries
Name 124895 0
Ken Pang
Address 124895 0
Murdoch Children's Research Institute
Royal Children's Hospital
50 Flemington Road, Parkville VIC 3052
Country 124895 0
Australia
Phone 124895 0
+61 393456991
Fax 124895 0
Email 124895 0
ken.pang@mcri.edu.au
Contact person for scientific queries
Name 124896 0
Ken Pang
Address 124896 0
Murdoch Children's Research Institute
Royal Children's Hospital
50 Flemington Road, Parkville VIC 3052
Country 124896 0
Australia
Phone 124896 0
+61 393456991
Fax 124896 0
Email 124896 0
ken.pang@mcri.edu.au

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
No/undecided IPD sharing reason/comment
Not in ethical approval


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.